Sandra Horning

Administrative Appointments

• President, ASCO (2005 - 2006)
• President-Elect, ASCO (2004 - 2005)

Honors and Awards

• Alwin C. Rambar-James B. D. Mark Award for Excellence in Patient Care, Stanford University School of Medicine (2000)

Current Research Interests

The objectives of the clinical research program are:
1. to improve therapeutic outcomes and/or reduce complications of treatment, and
2. to further elucidate the underlying biology of Hodgkin’s disease (HD) and the non-Hodgkin’s lymphomas (NHL).

The research program is highly collaborative and includes ongoing clinical trials with myeloablative therapy in HD and NHL with the Bone Marrow Transplant team, combined modality trials in HD with Radiation Oncology, clinical-pathologic correlative studies with Pathology, and drug development with an emphasis on targeted therapy for B-cell lymphoma (anti-CD20) with industrial collaborators.

Dr. Horning is chairman of the Lymphoma Committee for the Eastern Cooperative Oncology Group, a forum for extending pilot studies to multi-institutional trials. Dr. Horning supervises a sophisticated multi-relational Lymphoma Database which has information on over 15,000 patients, an excellent resource for prospective and retrospective clinical investigations

Clinical Trials

• Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
• Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for MCL Recruiting
• 90Y-IBRITUMOMAB Tiuxetan and AHCI with HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL Completed
• A Phase I Dose Escalation Study of Weekly SGN-35 Alone and in Combination With Gemcitabine in HL Completed
• A Pivotal Open-Label Trial of SGN-35 for Hodgkin Lymphoma No longer recruiting

Publications

• Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Horning SJ, Juweid ME, Schöder H, Wiseman G, McMillan A, Swinnen LJ, Advani R, Gascoyne R, Quon A. Blood. 2010; 115 (4): 775-7; quiz 918
• Cancer research and privacy: the problem with being joined at the hip. Horning SJ, J Clin Oncol. 2009; 27 (24): 3879-80
• Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Weinberg OK, Ma L, Seo K, Beck AH, Pai RK, Morales A, Kim Y, Sundram U, Tan D, Horning SJ, Hoppe RT, Natkunam Y, Arber DA. Am J Surg Pathol. 2009; 33 (4): 591-8
• Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. J Clin Oncol. 2009; 27 (10): 1607-14
• (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? Iagaru A, Wang Y, Mari C, Quon A, Goris ML, Horning S, Gambhir SS. Hell J Nucl Med. 2008 Sep-Dec; 11 (3): 153-6